Interaction between serotonin 5-HT1A receptors and beta-endorphins modulates antidepressant response

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1804-9. doi: 10.1016/j.pnpbp.2008.07.021. Epub 2008 Aug 3.

Abstract

Interactions between serotonergic and the endogenous opioid systems have been suggested to be involved in the etiopathogenesis of depression and in the mechanism of action of antidepressants. Activation of serotonin 5-HT1A receptors has been shown to increase plasma beta-endorphin (beta-END) levels in animal studies and in healthy humans.

Objectives: To assess interaction abnormalities between 5-HT1A receptors and the endogenous opioid system in patients with major depression and the possible modulating effect of citalopram.

Methods: The beta-END response to the 5-HT1A receptor agonist, buspirone (30 mg), was measured in 30 patients with major depression and in 30 age- and sex-matched healthy controls before and after an 8-week treatment with citalopram. Pre-treatment score of the Hamilton Rating Scale for Depression (HRSD) was >or=17. Antidepressant response was defined by a 50% decrease in the HRSD. Pre- and post-treatment maximum peak response (Deltamax) and the area under the curve (AUC) of beta-END response were compared. Three time points were measured (60, 90 and 120 min). We also examined the correlations between the beta-END response and the antidepressant response. Buspirone plasma levels were not measured.

Results: At baseline, beta-END response was similar in patients and controls. After 8 weeks of citalopram treatment depressed patients showed a significant decrease in the beta-END response (Deltamax: p<.001; AUC: p<.001). A significant correlation between the beta-END reduction in the response and the reduction in the HRSD score (r=.656; p<.001) was observed.

Conclusions: Changes in interaction between 5-HT1A receptor system and the endogenous opioid system may play a role both in the mechanism of action and response to antidepressant drugs.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Buspirone / therapeutic use
  • Case-Control Studies
  • Citalopram / therapeutic use
  • Depressive Disorder, Major / blood*
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / metabolism*
  • Female
  • Humans
  • Immunoradiometric Assay
  • Male
  • Middle Aged
  • Receptor, Serotonin, 5-HT1A / physiology*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Serotonin Receptor Agonists / therapeutic use
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Time Factors
  • Young Adult
  • beta-Endorphin / blood*

Substances

  • Serotonin Receptor Agonists
  • Serotonin Uptake Inhibitors
  • Citalopram
  • Receptor, Serotonin, 5-HT1A
  • beta-Endorphin
  • Buspirone